Comparison of effect that ticagrelor and triple antiplatelet therapy affect platelet reactivity

Abstract

High platelet reactivity (HPR) is associated with poor prognosis in coronary artery disease. Recently PLATO subgroup analysis showed that ticagrelor is better clinical outcome than the clopidogrel, which was related with low HPR. Also many studies reported that adjunctive cilostazol to dual antiplatelet therapy (DAPT) (so called triple antiplatelet therapy; TAT) is better clinical outcome than DAPT, which was associated with a greater antiplatelet effect at 30 days. Thus, this study was designed to compare the effect of ticagrelor and TAT on platelet reactivity with PRU and ARU values.